3 Steps for cell & gene therapy medical affairs teams to provide strategic value
A phrase often recited within the pharmaceutical and biotechnology industries in recent years is that medical affairs is the third strategic pillar of success,...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Ayushman Ghosh is Vice President in the Life Sciences Practice of CRA in New York. He has deep expertise in advising life sciences clients on commercial, clinical, medical, and manufacturing strategy in the gene therapy, rare disease, and oncology spaces.
Mr. Ghosh brings both an industry and consultant perspective to his work with life sciences companies. Prior to joining CRA he was SVP and led several practice areas, key partnerships, and biotech investments for a life sciences-focused boutique consulting firm, leading a team of 20+ consultants across major accounts and alliance partnerships with a focus on gene therapy, rare disease, and oncology. Previously, he drove commercial, market access, and corporate strategy engagements at Campbell Alliance (now Syneos Heath Consulting). He started his career as a scientist at Merck where he focused on process optimization and commercialization of novel biologics.